| First Author | Roghanian A | Year | 2015 |
| Journal | Cancer Cell | Volume | 27 |
| Issue | 4 | Pages | 473-88 |
| PubMed ID | 25873171 | Mgi Jnum | J:220304 |
| Mgi Id | MGI:5634201 | Doi | 10.1016/j.ccell.2015.03.005 |
| Citation | Roghanian A, et al. (2015) Antagonistic Human FcgammaRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo. Cancer Cell 27(4):473-88 |
| abstractText | Therapeutic antibodies have transformed cancer therapy, unlocking mechanisms of action by engaging the immune system. Unfortunately, cures rarely occur and patients display intrinsic or acquired resistance. Here, we demonstrate the therapeutic potential of targeting human (h) FcgammaRIIB (CD32B), a receptor implicated in immune cell desensitization and tumor cell resistance. FcgammaRIIB-blocking antibodies prevented internalization of the CD20-specific antibody rituximab, thereby maximizing cell surface accessibility and immune effector cell mediated antitumor activity. In hFcgammaRIIB-transgenic (Tg) mice, FcgammaRIIB-blocking antibodies effectively deleted target cells in combination with rituximab, and other therapeutic antibodies, from resistance-prone stromal compartments. Similar efficacy was seen in primary human tumor xenografts, including with cells from patients with relapsed/refractory disease. These data support the further development of hFcgammaRIIB antibodies for clinical assessment. |
